Definitive Healthcare Corp. (DH) shares ended the last trading session 8.4% higher at $5.01. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.4% gain over the past four weeks.Definitive Healthcare is benefiting from improved renewal rates, successful customer win-backs, and a focus on product offerings, including unified platform development and new solutions like Market Forecast and Monocl Conferences.This compa ...

FRAMINGHAM, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it has been named one of Built In’s 100 Best Places to Work in Boston, MA for 2025. The annual awards program includes companies of all sizes, from startups to large enterprises, and honors both remote-first employers as well as companies in large tech markets across the U.S. “We are honored to once again be recognized as a best place to work ...

Definitive Healthcare Corp. (DH) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a ...

A downtrend has been apparent in Definitive Healthcare Corp. (DH) lately with too much selling pressure. The stock has declined 5.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical in ...

FRAMINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Kevin Coop, and its Chief Financial Officer, Rick Booth, will present at the 27th Annual Needham Growth Conference. The Definitive Healthcare presentation is scheduled for Wednesday, January 15, 2025, at 2:15 p.m. Eastern Time. About Definitive HealthcareAt Definitive Healthcare, ou ...

Investors might want to bet on Definitive Healthcare Corp. (DH) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.The upward trend in estimate revisions for this company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation betw ...

Financial Data and Key Metrics - Total revenue for Q3 2024 was $62.7 million, down 4% year-over-year, but above the high end of the guidance range [8][31] - Adjusted EBITDA was $20.6 million, down 5% year-over-year, with an adjusted EBITDA margin of 33%, consistent with the prior year [8][31] - Adjusted net income grew 6% year-over-year to $15.4 million, with non-GAAP earnings per share increasing 5% to $0.10 [32] - Unlevered free cash flow was $24.3 million in Q3, and $85.2 million on a trailing 12-month basis, up 58% year-over-year [32][41] Business Line Performance - Subscription revenue decreased by low single digits, while professional services revenue declined more significantly [33] - The company ended Q3 with 530 enterprise customers, up 1 year-over-year but down 7 quarter-over-quarter [34] - Total customer accounts were approximately 2,570 at the end of Q3, down 200 year-over-year and 30 quarter-over-quarter [34] Market Performance - The company saw improvement in expansion sales activity compared to Q2, with some win-back customers returning [9] - Churn rates remained elevated, particularly in the life sciences market, impacting customer retention [10] - The company expects revenue to decline sequentially in Q4 and into early 2025, with a goal to return to sequential growth in the second half of 2025 [25][49] Strategic Direction and Industry Competition - The company is focusing on simplifying its product portfolio and developing a common platform to improve customer retention and upsell opportunities [11][15] - Two new product enhancements were introduced in Q3: Market Forecast and Monocl Conferences, aimed at improving customer value [20] - The company is committed to organic product development and strategic acquisitions to enhance its data and solutions [12] Management Commentary on Operating Environment and Future Outlook - Management highlighted the need for patience as operational changes take time to positively impact financial results [25] - The company expects continued revenue volatility in Q4 and 2025, with a focus on improving retention and reducing churn [25][49] - The Board approved a $100 million share buyback program, reflecting confidence in the company's long-term prospects [27] Other Important Information - The company recorded a $228.2 million goodwill impairment due to the current stock price, which is a noncash accounting charge [45] - The CFO, Rick Booth, will be leaving the company in June 2025, with a search process underway for his replacement [28] Q&A Session Summary Question: Demand Environment in Pharma and Life Sciences - The company noted modest improvement in some segments like provider and diversified, but pressures in life sciences remain, particularly due to delayed impacts from market improvements [55][57] Question: Growth Visibility for 2025 - The company expects revenue declines to moderate in 2025, with sequential growth returning in the second half of the year, but full-year revenue is expected to be down [63] Question: Competitive Environment - The company is not seeing significant competitive losses against major players like Veeva and IQVIA, with strong support from existing customers [81] Question: Unified Platform Strategy - The company is working on simplifying access to its products through a unified UI/UX interface, with further integration of back-office and data supply chain components expected to take longer [86][87] Question: Pricing Strategy - The company is considering a more sophisticated delivery mechanism to allow customers to optimize for service or price, while maintaining data quality leadership [83]

Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.09, delivering no surprise.Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Delaware 86-3988281 (State or other ...

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2024 Third quarter revenue exceeded guidance, and the Company announced a $100 million repurchase authorization Framingham, MA (November 7, 2024) – Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: • Revenue was ...